


Parkinson's Disease Biomarkers

Dear Researcher,

Levels of α -synuclein monomer and its oligomeric, aggregated and phosphorylated forms are well known to change in Parkinson's Disease. An excellent review by [Parnetti *et al.* \(2019\)](#), published in *Lancet Neurology*, discusses the Biomarker potential of α -synuclein isoforms and their clinical utility.

Biosensis is addressing the need for reliable and accurate quantification of α -synuclein by releasing its **NEW Rapid™** ELISA Kit for this important target ([BEK-2216](#)). It represents the first assay in Biosensis' collection of α -synuclein ELISA kits, with more kits in development!





Our new α -synuclein *Rapid*[™] ELISA Kit features:

- Real validation data on accurate quantification in human blood and CSF
- Low intra- and inter-assay CVs of < 10%
- Complete kit with precise instructions
- Fast (< 4 hours) and reliable assay performance

For a limited time only, Biosensis offers a 2-plate kit for the price of a 1-plate kit*. That's a saving of US\$368.50!

For more details on our α -synuclein *Rapid*[™] ELISA Kit, please find our protocol [here](#), or contact us at biospeak@biosensis.com.

Good luck with your research,

The Biosensis Team

*One order per customer, direct customers only. Quote "SYNUCLEIN" on your order and send to sales@biosensis.com. Offer valid until January 31, 2020.